What are the Historical Developments and Current Growth Metrics of the Biologics Market?
The biologics market has seen considerable growth due to a variety of factors.
• The expansion of the biologics market has been swift over the recent years. It's expected to balloon from $533.36 billion in 2024 to $610.25 billion in 2025, boasting a compound annual growth rate (CAGR) of 14.4%.
Factors such as an aging demographic, governmental efforts, capacity to demand high costs, and a growing demand for immunology are all contributors to the previously observed growth.
What Will Be The Biologics Market Size In The Future?
The biologics market is expected to maintain its strong growth trajectory in upcoming years.
• Accelerated expansion is anticipated in the biologics market over the next few years, reaching approximately $1068.24 billion by 2029 with a compound annual growth rate (CAGR) of 15.0%.
Various factors contributing to this projected growth include an upsurge in funding, technological advances, expanded access to healthcare, robust R&D aimed at the creation of oral biologics, the preference for pills over injections, and an increasingly strong pipeline of biologics. The forecast period is also set to witness key trends such as taking advantage of updated and more relaxed regulations to create new and better biologics, a shift towards biologic drug development, increased allocation of resources towards R&D for innovative biologics, and the heightened investment in research and development of biologics for treating complex diseases.
Which Drivers Are Accelerating Growth In The Biologics Market?
The burgeoning interest for personalised medicine is fuelling a significant expansion in the worldwide biologics market. Personalised medicine, also referred to as precision medicine, advocates a medical solution that is customised to the unique attributes of each patient. It paves the way for the modification of biological treatments to match a patient's distinct genetic and clinical profile, hence revolutionising the healthcare field. For instance, the Personalized Medicine Coalition, a hospital and healthcare establishment based in the US, stated in February 2024 that in 2023, the FDA gave the green light to 16 new personalised treatments meant for patients with rare diseases, marking an increase from just six in 2022. Consequently, the escalating demand for personalized medicine is propelling the advancement of the biologics market in the future.
What are the Market Segments in the Biologics Market?
The biologics market covered in this report is segmented –
1) By Type: Monoclonal Antibodies (MAbS), Therapeutic Proteins, Vaccines
2) By Drug Classification: Branded Drugs, Generic Drugs
3) By Route Of Administration: Oral, Other Route Of Administration
4) By Mode Of Purchase: Prescription-Based Drugs, Over-The-Counter Drugs
5) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies Or Drug Stores, Other Distribution Channels
Subsegments:
1) By Monoclonal Antibodies (MAbs): Naked Monoclonal Antibodies, Conjugated Monoclonal Antibodies, Bispecific Monoclonal Antibodies
2) By Therapeutic Proteins: Hormones, Enzymes, Cytokines, Fusion Proteins
3) By Vaccines: Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines
Pre-Book The Biologics Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What Trends are Shaping the Biologics Market?
To cement their market standing and outdo competition, leading corporations in the biologics sector are focusing on the production of novel products like oncology biosimilars. These biologics, which closely resemble existing biologic drugs, are utilized to combat cancer. For instance, Biocon Biologics Limited, a division of the Indian biopharmaceutical corporation, Biocon Limited and Viatris Inc., a pharmaceutical firm based in the United States, introduced a cancer biosimilar called Abevmy in Canada in May 2022. Biosimilar medications like Abevmy are biological products that bear a high resemblance to pre-approved biological medication and are used for treating identical conditions, offering the same level of safety and efficacy.
Who Are the Key Players in the Biologics Market?
Major companies operating in the biologics market include:
• Merck & Co.. Inc.
• AbbVie Inc.
• F. Hoffmann-La Roche AG
• Johnson & Johnson
• Pfizer Inc.
• Bristol Myers Squibb Company
• Sanofi S.A.
• GlaxoSmithKline Plc.
• Eli Lilly and Company
• Amgen Inc.
• Wockhardt
• Zydus Cadilla
• China Biologic Products Holdings Inc.
• ABLbio
• Adimmune
• Henlius
• Innovent Biologics
• Bio-Thera
• Hisun Pharma
• 3SBio
• Beijing ShuangLu Pharmaceuticals
• Qilu Pharmaceutical
• Biocon
• Dr.Reddy’s
• Mylan
• Kyowa Hakko Kirin
• Takeda
• Mitsubishi Tanabe
• AGC Biologics
• Tonghua Dongbao Pharmaceutical Co.
• China Regenerative Medicine International
• Shanghai Fosun Pharmaceuticals
• Bayer AG
• Novartis AG
• BiosanaPharma
• WuXi
• Teva UK Limited
• AstraZeneca
• Abbott Laboratories
• Vectura Group
• Fujifilm
• Lonza
• Seqens
• Piramal Pharma Solutions
• Corden Pharma
• Procos SpA and BSP Pharmaceuticals.
• Microgen
• Geropharm
• Valenta
• NovaMedica
• SynBi
• Rani Therapeutics
• Enteris BioPharma
• Allena Pharmaceuticals
• Biogen Inc.
• Emisphere Technologies Inc.
• Biogen Inc.
• Apotex
• Gilead Sciences
What are the Regional Insights into the Biologics Market?
North America was the largest region in the biologics market in 2024. Middle East is expected to be the fastest growing region in the forecast period. The regions covered in the biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
